Human Osteoprotegerin/TNFRSF11B Antibody

Catalog # Availability Size / Price Qty
AF805
AF805-SP
Osteoprotegerin/TNFRSF11B in Human Lymph Node.
3 Images
Product Details
Citations (7)
FAQs
Supplemental Products
Reviews (1)

Human Osteoprotegerin/TNFRSF11B Antibody Summary

Species Reactivity
Human
Specificity
Detects human Osteoprotegerin/TNFRSF11B in direct ELISAs and Western blots. In direct ELISAs, approximately 20% cross-reactivity with recombinant mouse Osteoprotegerin is observed.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human Osteoprotegerin/TNFRSF11B
Glu22-Leu401
Accession # AAB53709
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
0.1 µg/mL
Recombinant Human Osteoprotegerin/TNFRSF11B (Catalog # 185-OS)
Immunohistochemistry
5-15 µg/mL
See below
Neutralization
Measured by its ability to neutralize Osteoprotegerin/TNFRSF11B-mediated inhibition of cytotoxicity in the L‑929 mouse fibroblast cell line. The Neutralization Dose (ND50) is typically 0.25-0.7 µg/mL in the presence of 0.1 µg/mL Recombinant Human Osteoprotegerin/TNFRSF11B, 20 ng/mL Recombinant Human TRAIL/TNFSF10, a cross‑linking antibody, Mouse polyHistidine Monoclonal Antibody, and 1 µg/mL actinomycin D.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Examples

Immunohistochemistry Osteoprotegerin/TNFRSF11B in Human Lymph Node. View Larger

Osteoprotegerin/TNFRSF11B in Human Lymph Node. Osteoprotegerin/TNFRSF11B was detected in immersion fixed paraffin-embedded sections of human lymph node using 15 µg/mL Goat Anti-Human Osteoprotegerin/TNFRSF11B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF805) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Immunohistochemistry Osteoprotegerin/TNFRSF11B in Human Lymph Node. View Larger

Osteoprotegerin/TNFRSF11B in Human Lymph Node. Osteoprotegerin/TNFRSF11B was detected in immersion fixed paraffin-embedded sections of human lymph node using Goat Anti-Human Osteoprotegerin/TNFRSF11B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF805) at 25 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific labeling was localized to the cytoplasm and plasma membrane of lymphocytes. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Neutralization Osteoprotegerin/TNFRSF11B Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human Osteoprotegerin/TNFRSF11B Antibody. View Larger

Osteoprotegerin/TNFRSF11B Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human Osteoprotegerin/TNFRSF11B Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050) (Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human Osteoprotegerin/TNF-RSF11B (Catalog # 185-OS) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human Osteoprotegerin/ TNFRSF11B (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human Osteoprotegerin/ TNFRSF11B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF805). The ND50 is typically 0.25-0.7 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Availability
Size / Price
Qty
RB01
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Osteoprotegerin/TNFRSF11B

Osteoprotegerin (OPG)/Osteoclastogenesis Inhibitory Factor (OCIF) is a member of the tumor necrosis factor receptor superfamily that lacks any apparent cell‑association motifs and exists as a soluble secreted protein. In the TNF superfamily nomenclature, OPG is referred to as TNFRSF11B. OPG was originally isolated by sequence homology as a TNF receptor family protein during a fetal rat intestine cDNA-sequencing project and subsequently shown to be involved in the regulation of bone density. OCIF was initially purified from the conditioned medium of human embryonic fibroblasts based on its ability to inhibit osteoclast development. Comparison of the amino acid (aa) sequences of human OPG and OCIF proteins revealed their identity. Human OPG/OCIF cDNA encodes a 401 aa residue precursor protein with a 21 aa residue putative signal peptide that is removed to generate the mature soluble protein. The amino-terminal half of OPG contains four cysteine-rich repeats characteristic of TNF receptor family members. The 204 residues of the carboxy-terminal OPG/OCIF was found to contain two death domain homologous regions in tandem. Human and mouse OPG share approximately 84% and 94% amino acid sequence identity, respectively, with the rat OPG. Natural OPG/OCIF has been found to exist predominantly as disulfide-linked dimers. Two TNF superfamily ligands, including the membrane proteins OPG ligand/TRANCE (tumor necrosis factor-related activation-induced cytokine)/ODF (osteoclast differentiation factor)/RANKL (receptor activator of NF kappa B ligand) and TRAIL (TNF-related apoptosis‑inducing ligand)/APO-2 ligand, have been shown to be the cellular ligands for OPG/OCIF. Each of these ligands has been shown to interact with additional TNF receptor family members, including RANK (with TRANCE) and TRAIL receptors 1 - 4 (with TRAIL). The roles of these receptor-ligands in osteoclastogenesis, apoptosis and in the immune system remains to be elucidated.

References
  1. Lacey, D.L. et al. (1998) Cell 93:165.
  2. Emery, J.G. et al. (1998) J. Biol. Chem. 273:14363.
  3. Yasuda, H. et al. (1998) Proc. Natl. Acad. Sci. USA 95:3597.
Entrez Gene IDs
4982 (Human); 18383 (Mouse)
Alternate Names
OCIF; OCIFMGC29565; OPG; OPGtumor necrosis factor receptor superfamily member 11B; Osteoclastogenesis inhibitory factor; Osteoprotegerin; TNFRSF11B; TR1; tumor necrosis factor receptor superfamily, member 11b

Product Datasheets

You must select a language.

x

Citations for Human Osteoprotegerin/TNFRSF11B Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

7 Citations: Showing 1 - 7
Filter your results:

Filter by:

  1. Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer
    Authors: I Gomes, BP de Almeida, S Dâmaso, A Mansinho, I Correia, S Henriques, R Cruz-Duart, G Vilhais, P Félix, P Alves, P Corredeira, NL Barbosa-Mo, L Costa, S Casimiro
    Oncotarget, 2020;11(19):1714-1728.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  2. Differential expression patterns of Toll Like Receptors and Interleukin-37 between calcific aortic and mitral valve cusps in humans
    Authors: A Kapelouzou, C Kontogiann, DI Tsilimigra, G Georgiopou, L Kaklamanis, L Tsourelis, DV Cokkinos
    Cytokine, 2019;116(0):150-160.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  3. Porphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiation induced by tumor necrosis factor-alpha and interleukin-1beta but suppresses that by interleukin-17A: importance of proteolytic degradation of osteoprotegerin by lysine gingipain.
    Authors: Akiyama T, Miyamoto Y, Yoshimura K, Yamada A, Takami M, Suzawa T, Hoshino M, Imamura T, Akiyama C, Yasuhara R, Mishima K, Maruyama T, Kohda C, Tanaka K, Potempa J, Yasuda H, Baba K, Kamijo R
    J Biol Chem, 2014;289(22):15621-30.
    Species: Bacteria - Porphyromonas gingivalis
    Sample Types: Recombinant Protein
    Applications: Western Blot
  4. Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability.
    Authors: Davaine J, Quillard T, Brion R, Laperine O, Guyomarch B, Merlini T, Chatelais M, Guilbaud F, Brennan M, Charrier C, Heymann D, Goueffic Y, Heymann M
    PLoS ONE, 2014;9(9):e107642.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  5. Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets.
    Authors: Chollet ME, Brouland JP, Bal dit Sollier C, Bauduer F, Drouet L, Bellucci S
    Br. J. Haematol., 2010;148(5):805-7.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  6. Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?
    Authors: Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MW, Coleman RE, Holen I
    Int. J. Cancer, 2006;118(8):1901-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  7. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
    Authors: Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D
    Am. J. Pathol., 2003;163(5):2021-31.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Human Osteoprotegerin/TNFRSF11B Antibody

Average Rating: 5 (Based on 1 Review)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human Osteoprotegerin/TNFRSF11B Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human Osteoprotegerin/TNFRSF11B Antibody
By Anonymous on 06/29/2016
Application: ELISA Sample Tested: Purified Standard Species: Human